Accéder au contenu
Merck
Toutes les photos(1)

Documents

C0682800

Cefazolin

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

Cephazolin

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C14H14N8O4S3
Numéro CAS:
25953-19-9
Poids moléculaire :
454.51
Code UNSPSC :
41116107
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

cefazolin

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

InChI

1S/C14H14N8O4S3/c1-6-17-18-14(29-6)28-4-7-3-27-12-9(11(24)22(12)10(7)13(25)26)16-8(23)2-21-5-15-19-20-21/h5,9,12H,2-4H2,1H3,(H,16,23)(H,25,26)/t9-,12-/m1/s1

Clé InChI

MLYYVTUWGNIJIB-BXKDBHETSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Cefazolin EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Pictogrammes

Health hazard
GHS08

Mention d'avertissement

Danger

Mentions de danger

H317,H334

Classification des risques

Resp. Sens. 1 - Skin Sens. 1

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Choose from one of the most recent versions:

Certificats d'analyse (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

T Osler et al.
Diseases of the colon and rectum, 29(2), 140-143 (1986-02-01)
The seventh case of probable cefazolin-induced pseudomembranous colitis is reported. Perforation of the colon necessitated sigmoid resection. The postoperative course was protracted, and illustrates the difficulty of managing advanced pseudomembranous colitis when the oral route of antibiotic administration is not
Nagaraju Konda et al.
Optometry and vision science : official publication of the American Academy of Optometry, 91(1), 47-53 (2013-11-12)
To investigate the utility of additional microbial analyses to detect the causative microorganism of microbial keratitis and to determine the strength of association between clinical variables. This retrospective study included 125 eyes of 123 people presenting with presumed infectious keratitis
Cheng-Kun Wu et al.
PloS one, 8(4), e61666-e61666 (2013-05-01)
Antibiotic prophylaxis with norfloxacin, intravenous ciprofloxacin, or ceftriaxone has been recommended for cirrhotic patients with gastrointestinal hemorrhage but little is known about intravenous cefazolin. This study aimed to compare the outcome of intravenous cefazolin and ceftriaxone as prophylactic antibiotics among
Angela Macaluso et al.
The journal of pain : official journal of the American Pain Society, 14(6), 604-612 (2013-06-04)
Repeated injections of the antibiotic ceftriaxone cause analgesia in rodents by upregulating the glutamate transporter, GLT-1. No evidence is available in humans. We studied the effect of a single intravenous administration of ceftriaxone in patients undergoing decompressive surgery of the
John D Turnidge
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 52(7), 917-924 (2011-03-24)
Clinical and Laboratory Standards Institute breakpoints for cefazolin against Enterobacteriaceae that were published in January 2010 have been revised by the Subcommittee on Antimicrobial Susceptibility Testing, based on the examination of recent data about in vitro activity, pharmacokinetic-pharmacodynamic characteristics and
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique